Performance of the RASGRP1/APTX gene pair as a predictor of response to tipifarnib in AML. (A) The overall survival of newly diagnosed patients with AML stratified by RASGRP1/APTX was plotted using Kaplan-Meier analysis. The median overall survival of those predicted to be responders or nonresponders was 433 and 73 days, respectively. (B) The overall survival of patients with relapsed/refractory AML stratified with the 2-gene classifier is shown. The median overall survival of those predicted to be responders or nonresponders was 154 and 56 days, respectively.